Hinge Health, Inc. (HNGE) - Stock Analysis

Last updated: Sep 20, 2026

Research Idea

Research content for general circulation. Not individualized advice. Methodology & Disclosures

Reported Q3 revenue grew 52% year over year, EPS beat expectations, and the 2026 outlook was raised. Shares gained about 12.5% over 21 sessions.

Loading chart data...

Idea window: 11/9/2026 – 11/16/2026Sector: Healthcare

AI Analyst Overview

Last Price
$105.78
Market Cap
$8.60B
1D Return
-2.15%
YTD Return
+127.73%

Loading chart data...

Valuation Metrics

P/E
50.9
P/B
28.6
P/S
10.7
EV/EBITDA
52.3
Div Yield
—

Fundamental Analysis

8.0

Key Financial Insights: • Profitability Rebound • Strong Cash Flow • Balance Sheet Risk HNGE's strong quarterly profitability and cash flow mark a major turnaround, but elevated valuation, dilution, and legacy balance-sheet deficits warrant caution.

Turnaround
ValuationRisk

Price Behavior

7.0

Key Price Behavior Insights: • Strong monthly gain • Resistance test • Pullback support Support Level: $92.30–$92.70 Resistance Level: $94.80–$94.90 HNGE gained 10.8% over the last month and remains bullish above its average, but traders should watch for a sustained break above $94.90 or a pullback toward $92.30–$92.70.

Bullish
Breakout

Sentiment & News

6.0

Key News Insights: • Technical Support • Heavy Insider Selling • Short Interest HNGE shows technical momentum and short-squeeze interest, but significant insider and institutional selling warrants caution.

HNGE
ShortSqueeze
AI

AI Summary

7.0
Positive

HNGE has reached a compelling profitability and cash-flow inflection, but at ~52x EV/EBITDA near all-time highs, investors should require continued upside in core MSK growth and margin durability before adding aggressively; Cylinder is upside optionality, not yet a proven value driver.

Profitability
ValuationRisk
CylinderAcquisition
AI summary updated 61 days ago

Description

Hinge Health develops software for musculoskeletal care, providing digital programs and services that support treatment of acute injuries, chronic pain and post-operative rehabilitation. The company also offers administrative and operational support to health plans and employers. Founded in 2012, it is headquartered in San Francisco, California.

Idea History

DateCloseTickerCompanySummaryStatusP/L
Nov 9Nov 16HNGEHinge Health, Inc.
Reported Q3 revenue grew 52% year over year, EPS beat expectations, and the 2026 outlook was raised. Shares gained about 12.5% over 21 sessions.
Closed-0.7%
Oct 5Oct 12HNGEHinge Health, Inc.
Headlines cite strong revenue growth and a higher 2026 outlook, while the latest quarter was profitable and free-cash-flow positive. Shares closed at a 21-session high on October 5, though the elevated valuation raises pullback risk.
Closed+6.6%
Jun 17Jun 24HNGEHinge Health, Inc.
Positive catalyst-plus-momentum setup: Q1 revenue grew 47% YoY to $182.3M, net income turned positive at $35.1M, free cash flow was $41.6M, and management raised full-year guidance. Product expansion, 24 state employee health plan clients, and strong ROI data support near-term sentiment.
Closed+5.3%
May 14May 21HNGEHinge Health, Inc.
Healthcare momentum candidate with strong execution: Q1 revenue was $182M, up 47% YoY and ahead of expectations, margins improved, management raised full-year revenue guidance, and Q1 free cash flow was $41.6M. Stock is up about 25% over the last 21 trading days with only a modest pullback from its recent high.
Closed+2.3%
Research content for educational purposes only. Not investment advice. All decisions are your responsibility.